Table 4.
Incidence of adverse events in the two study groups from inclusion to day 7 of follow up
| |
Day 1 |
Day 2 |
Day 3 |
Day 7 |
||||
|---|---|---|---|---|---|---|---|---|
| Adverse event | AM | AL | AM | AL | AM | AL | AM | MF |
| Dizziness (n,%) |
35 (22.3) |
17 (11.1) |
61 (38.8) |
8 (5.2) |
58 (38.1) |
11 (7.1) |
15 (10.2) |
6 (4.03) |
| Vomit (n,%) |
16 (10.2) |
11 (7.2) |
09 (5.7) |
0 |
04 (2.6) |
0 |
0 |
0 |
| Abdominal pain |
15 (9.5) |
11 (7.2) |
11 (7.2) |
10 (6.5) |
10 (6.5) |
4 (2.6) |
1 (0.66) |
0 |
| Pruritus (n,%) |
0 |
2 (1.3) |
0 |
1 (0.6) |
0 |
0 |
0 |
0 |
| Oral herpes (n,%) | 0 | 2 (1.3) | 0 | 3 (1.9) | 1 (0.66) | 3 (1.9) | 0 | 1 (0.67) |
AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.